Tools
Toolsand Canadian Antimicrobial Resistance Alliance (CARA) (2018) Analysis of multidrug resistance in the predominant Streptococcus pneumoniae serotypes in Canada:the SAVE study, 2011-15. Journal of Antimicrobial Chemotherapy, 73 (suppl_7). vii12-vii19. ISSN 0305-7453
Preview |
PDF (Accepted_Manuscript)
- Accepted Version
Download (525kB) | Preview |
Abstract
Objectives: This study assessed MDR invasive isolates of Streptococcus pneumoniae, in relation to serotype evolution in Canada between 2011 and 2015 as part of the annual SAVE study. Methods: As part of a collaboration between the Canadian Antimicrobial Resistance Alliance and Public Health Agency of Canada-National Microbiology Laboratory, 6207 invasive isolates of S. pneumoniae were evaluated. All isolates were serotyped and had antimicrobial susceptibility testing performed, in accordance with CLSI guidelines (M07-A10, 2015). Complete susceptibility profiles were available for 6001 isolates. MDR was defined as resistance to three or more classes of antimicrobial agents (with penicillin MIC ≥2 mg/L defined as resistant). Results: The overall rate of MDR S. pneumoniae was 6.2% (372/6001) in SAVE, decreasing significantly from 8.5% in 2011 to 5.6% in 2015 (P = 0.0041). MDR was observed in 32 serotypes, with serotypes 15A and 19A predominating (26.6% and 41.7% of the MDR isolates, respectively). The overall proportion of serotypes 19A, 7F and 33A decreased significantly (P < 0.0001) throughout the study. The annual proportion of serotypes 7C, 8, 9N, 10A, 20, 24F, 29, 31, 33F, 35B and 38 increased throughout the study; however, among these increasing serotypes, MDR was only notable (>5%) for 24F and 33F. Conclusions: In 2015, 56.3% of invasive MDR S. pneumoniae were serotypes included in the PCV-13 vaccine. PCV-13 includes the most commonly identified serotype, 19A; however, other increasingly important MDR serotypes, such as 15A, 24F and 33F, are notably not in the currently used vaccines.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | adolescent,adult,aged,pharmacology,canada,child,child, preschool,pharmacology,drug resistance, multiple, bacterial,humans,infant,infant, newborn,microbial sensitivity tests,middle aged,pharmacology,blood,administration & dosage,serogroup,serotyping,classification,pharmacology,young adult,sdg 3 - good health and well-being ,/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being |
| Faculty \ School: | Faculty of Medicine and Health Sciences > Norwich Medical School |
| Depositing User: | LivePure Connector |
| Date Deposited: | 07 Oct 2020 23:58 |
| Last Modified: | 03 Nov 2022 16:31 |
| URI: | https://ueaeprints.uea.ac.uk/id/eprint/77160 |
| DOI: | 10.1093/jac/dky158 |
Actions (login required)
 |
View Item |